Johnson & Johnson vs AbbVie: Divergent Growth Strategies in Q1 2026 Earnings
Both Johnson & Johnson (JNJ) and AbbVie (ABBV) exceeded revenue expectations for Q1 2026, with JNJ reporting $24.06 billion (+9.9% YoY), driven by TREMFYA's 68.3% growth and DARZALEX’s increase to $3.96 billion. AbbVie reported $15 billion in revenue (+12.4% YoY) led by Skyrizi ($4.48 billion, +30.9%) and Rinvoq ($2.12 billion, +23.3%). Both companies raised full-year guidance.
Topics: AbbVie guidance update Johnson & Johnson Q1 earnings revenue growth